LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

LLY

1,020.46

+0.27%↑

JNJ

245.53

+0.57%↑

ABBV

224.18

-1.38%↓

NVS

163.25

-1.1%↓

MRK

121.74

+0.84%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Avatud

SektorTervishoid

1.36 1.49

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.3

Max

1.37

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+246.72% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	3. märts 2026

Turustatistika
By TradingEconomics
Turukapital	18M 144M
Eelmine avamishind	-0.13
Eelmine sulgemishind	1.36

Uudiste sentiment

By Acuity

50%

165 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. veebr 2026, 22:31 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. veebr 2026, 22:18 UTC

Tulu

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. veebr 2026, 22:11 UTC

Tulu

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. veebr 2026, 21:52 UTC

Tulu

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. veebr 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. veebr 2026, 23:34 UTC

Market Talk

Tulu

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. veebr 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. veebr 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. veebr 2026, 22:45 UTC

Tulu

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. veebr 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q EPS $1.18 >NTR.T

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q Sales $5.34B >NTR.T

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q EPS $1.07 >PAAS

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q Rev $1.18B >PAAS

18. veebr 2026, 22:30 UTC

Tulu

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. veebr 2026, 22:29 UTC

Tulu

Kinross Gold 4Q EPS 75c >K.T

18. veebr 2026, 22:22 UTC

Tulu

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. veebr 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. veebr 2026, 22:16 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. veebr 2026, 22:05 UTC

Tulu

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. veebr 2026, 22:03 UTC

Tulu

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Sales $929M >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Adj EPS 67c >KGC

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Sales $2.02B >KGC

18. veebr 2026, 21:56 UTC

Tulu

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

246.72% tõus

12 kuu keskmine prognoos

Keskmine 4.75 USD 246.72%

Kõrge 7 USD

Madal 2.5 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

165 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.